Interlenkin-2 alone and in combination with other cytokines in melanoma: the investigational approach at the University of Texas M. D. Anderson Cancer Center
1989; Elsevier BV; Volume: 16; Linguagem: Inglês
10.1016/0305-7372(89)90021-2
ISSN1532-1967
AutoresDavid Parkinson, Moshe Talpaz, Kijung Lee, Sewa S. Legha, Avi B. Markowitz, K Itoh, Charles M. Balch, James L. Murray, A. Zukiwski, Robert S. Benjamin, Jordan U. Gutterman,
Tópico(s)Cutaneous Melanoma Detection and Management
ResumoThe clinical data that have been accumulated so far suggests a significant influence of IL-2 dose and schedule on the immunobiological effects and clinical toxicities observed with this cytokine. Consequently, the series of Phase I and Phase II clinical trials conducted at the University of Texas M. D. Anderson Cancer Center in patients with advanced malignant melanoma investigating the use of IL-2 in combination with other cytokines, monoclonal antibodies, or ex vivo activated effector cells have used a common dose and schedule of IL-2 administration for which abundant immunobiological information already exists. This approach allows cross-trial comparison of experience with toxicities, immunobiological observations and clinical activity by a group of investigatiors within a single institution, and more rapid and valid evolution towards combination biological therapy, which preclinical data suggest will have greater activity than single agent therapy.
Referência(s)